Lead Sponsor

Merck Sharp & Dohme LLC

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Yes

•Body mass index (BMI) ≥18.5 kg/m\^2 and ≤35 kg/m\^2
•Healthy participants: Baseline estimated glomerular filtration rate (eGFR) ≥90 mL/min based on the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine equation
•Severe renal impairment participants: Baseline estimated glomerular filtration rate (eGFR) \<30 mL/min based on the 2021 CKD-EPI Creatinine equation

•Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)
•History of major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit
•Severe renal impairment participants:
•History or presence of renal artery stenosis
•Had a renal transplant
•Currently taking medications to treat chronic medical conditions associated with renal disease if participant has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of medication(s) within 4 hours prior to and 8 hours after administration of the study drug

Related studies

NCT07154901 · Renal Impairment

NCT07165015 · Renal Impairment, Healthy, and more

NCT06693765 · Renal Impairment, End-stage Kidney Disease, and more

NCT06352411 · Healthy, Renal Impairment

NCT06835127 · Renal Impairment, Limb Ischemia, Critical

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)